Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 
If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Designation of authorised representative 

The manufacturers can designate only one authorised representative per generic device group, and the designation is valid when accepted in writing. The manufacturer and the authorised representative can structure their contractual relationship as appropriate, but a written mandate is necessary whether the authorised representative is independent or part of the same larger organization as the manufacturer. 

A manufacturer can only delegate certain obligations to their authorised representative, not being possible to delegate: 

  • The obligations laid down in MDR Article 10(1), (2), (3), (4), (6), (7), (9), (10), (11) and (12) 
  • The obligations laid down in IVDR Article 10(1), (2), (3), (4), (5), (6), (8), (9), (10) and (11) 

The designation of authorised representatives is verified by the importers. To do this, they must check if the authorised representative’s name appears on relevant documentation such as the EU declaration of conformity, relevant certificates, and device labelling. Moreover, the designation could be verified using the EUDAMED database.  

Registration of authorised representative 

The authorised representatives must register its details in EUDAMED. 

The information provided include:  

  • Type of economic operator (authorised representative) 
  • Name, address and contact details of the economic operator 
  • If the submission is carried out by another person on behalf of the economic operator: the name, address and contact details of that person 
  • Name address and contact details of the PRRC. 

In addition to registration, the authorised representative must check the accuracy of the data up to one year after the initial submission (and every second year thereafter) and must assure that the information is updated within one week after any change.  

The management of mandates for authorised representatives in EUDAMED, including termination of a mandate, is provided in the “EUDAMED: Economic Operator user guide”, available HERE!.  

Other responsibilities of authorised representative 

The responsibilities of authorised representatives are summarized in the table below. 

Verify manufacturer’s UDI and registration obligations Manufacturer’s obligation to register its information and devices in EUDAMED cannot be delegated, however, the authorised representative must verify that the manufacturer has complied with its UDI and devices registration.  
Verify EU Declaration of Conformity, technical documentation, and conformity assessment procedure The authorised representative verifies that the EU declaration of conformity and technical documentation have been drawn up and that an appropriate conformity assessment procedure has been carried out.  
Keep documents The authorised representative must keep a copy of the technical documentation, the EU declaration of conformity and, if applicable, a copy of the relevant certificate at the disposal of competent authorities for a period of at least 10 years after the last device covered by the EU declaration of conformity has been placed on the market, and in the case of implantable devices, a period of at least 15 years after the last device has been placed on the market. Apart from the copy of the technical documentation, the EU declaration of conformity and the copy of the relevant certificate, the authorised representative must also keep depending on the situation: The documentation on the manufacturer’s quality management system Information on changes The decisions and reports from the notified body copies of scientific opinions and reports and their additions/supplements 
Demonstrate that documents were verified The authorised representative should maintain open communication lines with the manufacturer and verify that the necessary documentation has been drawn up and up to-date. The authorised representative must demonstrate to the competent authority that those verifications have been performed. 
Inform the manufacturer about complaints The authorised representative must immediately inform the manufacturer about complaints and reports from healthcare professionals, patients and users about suspected incidents related to the device. 
Cooperate with the competent authority Upon request from a competent authority, the authorised representative must provide all the information necessary to demonstrate the conformity of a device, in an official Union language determined by the Member State concerned. The authorised representative should forward to the manufacturer any request by a competent authority for device samples or access to device and should verify that this was accomplished.  The authorised representative must cooperate with the competent authorities on any preventive or corrective action taken to eliminate or mitigate the risks posed by devices. Meeting this requirement may involve the authorised representative coordinating and communicating with importers and distributors and other entities in the supply chain. 

Liability of authorised representative  

If the manufacturer has not complied with the general obligations (MDR/IVDR Article 10), and did not delegate its obligations, the authorised representative remains legally liable for defective devices on the same basis as, and jointly and severally with, the manufacturer. 

Therefore, the authorised representative can be liable if:  

  • The manufacturer’s liability for a defective device is established under applicable Union or national law (e.g. Product liability Directive 85/374/EEC transposed into national law), and; 
  • It is established that the manufacturer has not complied with the general obligations (MDR/IVDR Article 10). 

Thus, the authorised representative may have a particular interest to verify that the manufacturer has fulfilled its obligations, including the obligation to provide sufficient financial coverage (Liability insurance).  

The liability “on the same basis as the manufacturer”, means that if liability is alleged under an applicable Union or national law, the authorised representative has the same rights to defend itself as the manufacturer under that regime. 

The liability would ultimately be decided by the competent courts.  

Termination of mandate  

The authorised representative has the right to terminate the mandate if the manufacturer acts contrary to its obligations under the Regulations.  

An authorised representative who terminates its mandate because of the abovementioned, shall immediately inform the competent authority and, if applicable, the notified body involved in the conformity assessment. In the event of a problematic termination, the authorised representative is advised to inform of the extent of the manufacturer’s non-compliance. 

If the authorised representative terminates the mandate, it should still cooperate with the competent authorities for devices placed on the market during the period in which it was designated. This is especially relevant if no new authorised representative has yet been designated for those devices. 

Change of authorised representative 

In general, a tripartite agreement should exist to change the authorised representative, except if the outgoing authorised representative ceases to exist, are no longer traceable or, for other reasons properly justified.  

That agreement shall address  

  • The date of termination of the mandate of the outgoing authorised representative and date of beginning of the mandate of the incoming authorised representative 
  • The date until which the outgoing authorised representative may be indicated in the information supplied by the manufacturer 
  • The transfer of documents, including confidentiality aspects and property rights 
  • The obligation of the outgoing authorised representative to forward to the manufacturer or incoming authorised representative any complaints or reports about suspected incidents. 

Person Responsible for Regulatory Compliance (PRRC)  

The authorised representatives shall have permanently and continuously at their disposal at least one PRRC.  

There should be a clear contractual relationship in place between the authorised representative and the PRRC. The authorised representatives whose mandate with the manufacturer covers “legacy devices”, are not required to appoint a PRRC.  

Market Surveillance  

In addition to the responsibilities previously stated, the authorised representatives: 

  • may be consulted in the context of market surveillance measures taken by competent authorities
  • may be required to make documentation available to competent authorities as part of their market surveillance activities  
  • may be subject to announced and unannounced inspections by the competent authorities as part of their market surveillance activities 

further
reading

cosmetic products

United Kingdom Restricts the Use of BHT in Cosmetic Products

The United Kingdom has taken a significant step in regulating the use of Butylated Hydroxytoluene (BHT) in cosmetic products. This move is crucial for distributors, manufacturers, and importers to ensure compliance and maintain the safety of their products in the UK market.

Read More »
cosmetic products

Great Britain Mandatory Classification List (MCL): cosmetic ingredients added.

On March 12, 2024, the Health and Safety Executive (HSE) updated the GB Mandatory Classification List (MCL) by adding 25 new chemical substances, as mandated by Article 37 of the GB Classification, Labelling and Packaging (CLP) Regulation. This update impacts substances identified as cosmetic ingredients with proposed Carcinogen, Mutagen, or Reprotoxic (CMR) classifications under Article 15 of the UK Cosmetics Regulation (UKCR). Notably, 2-ethylhexanoic acid and its zinc salt, along with Dimethyltolylamine, are among those facing potential bans and additions to the UK Cosmetics Regulation’s Annex II. These changes will come into effect on September 2, 2025.

Read More »
cosmetic products

New coating for TiO2 (nano) – is it safe?

The Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on new coating for Titanium Dioxide (nano). It declared the data was not enough to draw conclusions regarding the safety of this alternative coating, as more evidence of similarity to other nanomaterials is necessary.

Read More »
cosmetic products

New EU cosmetic restrictions on Cyclic Volatile Methyl Siloxanes (cVMS)

Cyclic volatile methyl siloxanes (cVMS) have raised environmental concerns because of their persistence and bioaccumulative properties. In light of these concerns, the European Union has extended restrictions on substances like D4, D5, and D6 in cosmetic products. New regulations will further limit the concentration of these compounds in both rinse-off and leave-on products, with compliance deadlines set for 2026 and 2027.

Read More »
cosmetic products

Citral under review: SCCS Preliminary Opinion

The SCCS was tasked by the European Commission to evaluate if the safety levels for Citral, determined through QRA2 based on skin sensitization induction, are sufficient to safeguard consumers. A preliminary opinion was released.

Read More »
cosmetic products

Are sunscreens with Benzophenone-4 safe?

Benzophenone-4 is commonly known as a UV-filter in cosmetic products. Learn what the final opinion of SCCS states about Benzophenone’s safety profile as a UV-filter in cosmetic products.

Read More »
cosmetic products

Is Aluminium in cosmetics safe for human health?

The Scientific Committee on Consumer Safety (SCCS) published its Final Opinion on the safety of Aluminium in cosmetic products. This follows a lengthy review process that began in 2013 when the SCCS was first mandated to evaluate the potential health risks of Aluminium (Al) and its compounds in cosmetics.

Read More »
cosmetic products

Silver in Cosmetics: SCCS preliminary opinion.

Ingredients: SILVER

The recent preliminary opinion from the Scientific Committee on Consumer Safety (SCCS) regarding silver in cosmetics is crucial for consumers and manufacturers. This article breaks down the key points, making it easier to understand the implications and stay informed.

Read More »
news & updates

EU Ecolabel adoption and recognition are on the rise

The Ecolabel certification is a comprehensive program focused on fostering sustainable practices. It evaluates products based on life cycle assessments, where every phase of said life cycle must abide by strict standards to attain the Ecolabel certification. The overarching objective of this certification is minimizing environmental harm from production or consumption activities.

Read More »